Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
نویسندگان
چکیده
منابع مشابه
A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
The incretins glucagon-like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) are growth factors with neuroprotective properties. GLP-1 mimetics are on the market as treatments for type 2 diabetes and are well tolerated. Both GLP-1 and GIP mimetics have shown neuroprotective properties in animal models of Parkinson's and Alzheimer's disease. In addition, the GLP-1 mimetic...
متن کاملiology of Incretins: GLP-1 and GIP
his review focuses on the mechanisms regulating he synthesis, secretion, biological actions, and herapeutic relevance of the incretin peptides gluose-dependent insulinotropic polypeptide (GIP) nd glucagon-like peptide-1 (GLP-1). The pubished literature was reviewed, with emphasis on ecent advances in our understanding of the biolgy of GIP and GLP-1. GIP and GLP-1 are both ecreted within minutes...
متن کاملIncretin effect: GLP-1, GIP, DPP4.
The term incretin effect was used to describe the fact that oral glucose load produces a greater insulin response than that of an isoglycemic intravenous glucose infusion. This difference has been attributed to gastrointestinal peptides GLP-1 and GIP. Since incretin effect is reduced in subjects with type 2 diabetes, despite GLP-1 activity preservation, two forms of incretin-based treatment hav...
متن کاملGLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel thera...
متن کاملGLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
In this issue of Diabetes, two articles describe preclinical studies evaluating the effects of chronic glucagon-like peptide 1 (GLP-1)–based therapy on development of pancreatitis and pancreatic neoplasia (1,2). These studies were performed in light of recent case reports and a case-control study suggesting that diabetic individuals using sitagliptin or exenatide have a several-fold increased l...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JCI Insight
سال: 2020
ISSN: 2379-3708
DOI: 10.1172/jci.insight.140532